Displaying drugs 10201 - 10225 of 12589 in total
Etrolizumab
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
Matched Description: … in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal leukoencephalopathy ... [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted ... gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of …
Managlinat dialanetil
CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Investigational
Matched Description: … enzymes of gluconeogenesis. ... CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting …
AX200
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
Matched Description: … stroke, while stimulating simultaneously the regeneration of nervous tissue through the induction of ... is halfway through the process of gaining clinical approval. ... neuro- and arteriogenesis and supporting the reorganisation of the nervous system. …
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … of coronary artery disease. ... , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment ... TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical …
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Matched Description: … of activity in models of epilepsy. ... ICA-105665 is a novel small molecule compound for the treatment of epilepsy. ... In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. …
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over ... The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
SC12267
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
Matched Description: … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating ... cells, especially of lymphocytes, which are important for the immune response. ... ) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. …
Platelet Lysate
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Matched Description: … [A220188] It is extracted through lysis of the plasma membrane of platelets. ... Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular ... Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory ... protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG. …
ATL1101
ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Investigational
Matched Description: … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis ... a protein involved in the regulation of cell overgrowth in psoriasis. ... ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, …
BMS-919373
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
Investigational
Matched Description: … BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on ... the Electrical Activity of the Heart Using Pacemakers). …
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Description: … of an earlier onset of action compared to antidepressants already on the market. ... a desired "triple-mode-of-action". ... with a new, unique drug profile expected to yield important benefits compared to existing treatments of …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … of atherosclerosis. ... to sites of inflammation. ... Plozalizumab has been investigated for the treatment of Atherosclerosis. …
Go-6976
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Description: … An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007] …
Ciraparantag
Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
Investigational
Matched Description: … Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban). ... Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single …
Paliroden
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
Matched Description: … Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature ... Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous …
CP-39,332
CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency. However, none of the members of this stereoisomers has been marketed.
Experimental
Matched Description: … However, none of the members of this stereoisomers has been marketed. ... It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP …
GB-13
GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
Investigational
Matched Description: … mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A. ... GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered …
NTx-265
NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause of death worldwide. In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of...
Investigational
Matched Description: … of death worldwide. ... NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and ... In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. …
Tallimustine
Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as brostallicin, which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA...
Experimental
Matched Description: … minor groove of DNA. ... Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the ... [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour …
Efavaleukin alfa
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
Investigational
Matched Description: … G Fc domain by way of a G4S linker. ... Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin ... It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With …
Entolimod
Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
Investigational
Matched Description: … , Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among ... Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer …
PI-103
PI-103 is an inhibitor of p110α of class I PI3K.
Investigational
Matched Description: … PI-103 is an inhibitor of p110α of class I PI3K.[A253092] …
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
Matched Description: … WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing ... Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of …
MUL001
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
Matched Description: … MUL001 is live attenuated strain of _Salmonella typhimurium_ being investigated for the treatment of …
Displaying drugs 10201 - 10225 of 12589 in total